Health Care & Life Sciences » Pharmaceuticals | Boston Therapeutics Inc.

Boston Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
4,601.50
4,699.90
2,489.80
3,737.50
1,584.90
3,601.20
Depreciation, Depletion & Amortization
67.10
70.90
71.00
70.40
67.00
159.90
Other Funds
2,064.90
929.40
768.30
2,232.10
150.60
1,942.70
Funds from Operations
2,469.50
3,699.60
1,650.50
1,435.10
1,367.20
1,498.60
Changes in Working Capital
130.10
225.40
355.50
185.40
92.00
614.80
Net Operating Cash Flow
2,339.40
3,474.10
1,295.00
1,249.60
1,275.20
883.80
Capital Expenditures
10.90
6.50
-
-
4.70
Net Investing Cash Flow
10.90
6.50
-
-
4.70
Issuance/Reduction of Debt, Net
-
-
978.70
1,895.80
180.00
Net Financing Cash Flow
5,185.40
250.50
1,178.70
1,895.80
730.00
Net Change in Cash
2,835.10
3,230.20
116.30
646.20
549.90
Free Cash Flow
2,350.30
3,480.70
1,295.00
1,249.60
1,279.90
Change in Capital Stock
5,185.40
250.50
200.00
-
550.00

About Boston Therapeutics

View Profile
Address
354 Merrimack Street No. 4
Lawrence Massachusetts 01843
United States
Employees -
Website http://www.bostonti.com
Updated 07/08/2019
Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products are designed to help manage blood sugar, treat pre-diabetes, and diabetes related pathologies. Its drug candidates comprises of BTI320, BTI-410, and IPOXYN.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.